N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
N/A N=109 Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01
Phase 4 N=226 Stress Neuroadaptation in Tobacco Dependence
Nicotine Dependence
Primary: Overall Stressor Reactivity — 25.1; 22.5; 32.3; 16.9 microvolts
N/A N=224 Treating Tobacco Dependence in Inpatient Psychiatry - 1
Tobacco Use Cessation · Tobacco Use Disorder
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 3; 14; 6; 14 Participants — p=0.018
N/A N=412 Group Therapy for Nicotine Dependence: Mindfulness and Smoking
Smoking · Tobacco Use Cessation
Primary: Number of Participants With Smoking Abstinence — 21; 39; 43 Participants
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
Phase 4 N=20 Treatment of Nicotine Dependence and Acute Depression
Major Depressive Disorder · Nicotine Dependence
Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001
Phase 2 N=12 Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
Cannabis Dependence · Nicotine Dependence
Primary: Cigarette Use — 12.6; 2.1 cigarettes/day
Phase 4 N=1,504 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
Phase 2 N=184 Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants
Phase 3 N=74 Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence
Smoking Cessation
Primary: Change in the Skin Conductance Level, Caused by Smoking Cues, Measured Using Script Driven Imagery — 0.107; -0.040 µS — p=0.05
Phase 2 N=40 Varenicline for Treatment of E-cigarette Dependence
Smoking Cessation
Primary: Number of Participants Abstinent From Vaping at Week 8 — 9; 6 Participants
N/A N=18 Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
Copd · Smoking Cessation · Nicotine Dependence
Primary: Number of Participants Who Achieved 24-hour Smoking Abstinence at End-of-treatment — 1; 1; 2 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=25 Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging
Nicotine Dependence
Primary: Change in Mu-opioid Receptor Binding Potential (BP) Between Baseline and Post-patch Scans — -2.47; -5.94; 5.60; -1.24 ratio
N/A N=245 Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
Tobacco Dependence
Primary: Number of Participants Who Dropped Out of Study as a Measure of Adherence — 52; 19 Participants — p=<0.0001
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=12 Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Tobacco Use Disorder
Primary: Cigarette Choice After 3 Day Abstinence — 2.50; 3.67 number of cigarette choices (0-6)
Phase 2 N=243 Selegiline Patch for Treatment of Nicotine Dependence
Tobacco Use Disorder
Primary: Expired-air Carbon Monoxide Confirmed Smoking Abstinence — 24; 25 participants not smoking
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
Phase 2 N=24 Varenicline and Smoking Cessation in Schizophrenia
Schizophrenia · Smoking Cessation
Primary: Smoking Abstinence - Serum/Urine Measurements — 198.67; 207; 213.8; 22.57 ng/mL — p=>0.05
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
Early Phase 1 N=16 Nicotine's Potential Abuse With Menthol
Nicotine Dependence
Primary: Drug Effect Questionnaire - Stimulatory Effects — 39.37; 33.48; 32.35; 33.23 units on a scale — p=0.93
N/A N=184 Brain Nicotine Receptor Density in Veteran Smokers
Positron Emission Tomography
Primary: PET Scan, Rating Scales — 7.1; 8.6; 7.9; 8.0 Vt/fp or mL/cm3
Phase 4 N=820 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
Tobacco Use Disorder
Primary: 12 Month Prolonged Abstinence From Tobacco Measured at 12 Months From Completion of Intervention. — 169; 321; 318 participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=300 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Nicotine Dependence · Major Depressive Disorder
Primary: Bioverified Point-prevalence Abstinence at 27 Weeks — 6; 3; 13; 13 Participants
Phase 2 N=131 Varenicline Treatment of Alcohol Dependence in Smokers
Alcoholism · Alcohol Abuse · Smoking
Primary: Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment — 2.07; 2.25 log transformed percentage of days